A Post-Actavis Approach To Reverse Payment Settlements

Law360, New York (July 31, 2013, 3:00 PM EDT) -- In Federal Trade Commission v. Actavis Inc., the U.S. Supreme Court held that "reverse payment" pharma patent settlements are not categorically immune from the antitrust laws even when within the scope of the patent.[1] Instead, the court decided that such settlements between innovator and generic drug companies may (or may not) violate the Sherman Act....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!